|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
on1086128396 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
190216s2019 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDX
|d OCLCQ
|d N$T
|d OCLCF
|d UKAHL
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCL
|d OCLCQ
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1085698771
|
| 020 |
|
|
|a 9781681084459
|q (electronic bk.)
|
| 020 |
|
|
|a 1681084457
|
| 035 |
|
|
|a (OCoLC)1086128396
|z (OCoLC)1085698771
|
| 050 |
|
4 |
|a RC660
|
| 049 |
|
|
|a HCDD
|
| 100 |
0 |
|
|a Atta-ur-Rehman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research.
|n Volume 4,
|p Diabetes and Obesity
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2019.
|
| 300 |
|
|
|a 1 online resource (280 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - Diabetes and Obesity Ser. ;
|v v. 4
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Cover; Title; Biblography; End User License Agreement; Contents; Preface; List of Contributors; Pharmacologic Obesity Treatment -- Emphasis on Efficacy and Cardiometabolic Markers; Fariha Salman1, Ivan Gerling2 and Helmut O. Steinberg*, 2; INTRODUCTION; Weight-Loss Drug Decreasing Food Absorption; Weight-Loss Drugs Decreasing Food Intake; Combination of Topiramate and Phentermine; Combination of Naltrexone and Bupropion; Liraglutide; Summary; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES
|
| 505 |
8 |
|
|a Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic ComplicationsJessica Felton1 and Jean-Pierre Raufman2,*; INTRODUCTION AND OVERVIEW; Bile Acid Synthesis & Circulation; Bile Acid Feedback Mechanisms; TAKEDA G PROTEIN-COUPLED RECEPTOR-5 (TGR5); TGR5 & Immunity; TGR5 in the Liver and Gallbladder; TGR5 & Thyroid Hormone Activation; GLUCAGON-LIKE PEPTIDE 1 (GLP-1); Physiology of GLP-1; Effects of GLP-1; Pathophysiology of GLP-1; THE ROLE OF TGR5 IN GLP-1 SECRETION; THE ROLE OF FXR IN GLUCOSE HOMEOSTASIS
|
| 505 |
8 |
|
|a MANIPULATING THE BILE ACID POOL FOR GLUCOSE HOMEOSTASISBILE ACIDS & GLP-1 AFTER BARIATRIC SURGERY; Glucose Homeostasis following Gastric Bypass Surgery; Increased Bile Acid Levels after Gastric Bypass Surgery; PHARMACOLOGY; GLP-1 Agonists; DPP4 Inhibitors; TGR5 Agonists; FUTURE DIRECTIONS; CONCLUSIONS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Sodium-Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus: The 'New Kids on the Block' in the Era of Evidence-based Medicine; Cheow Peng Ooi1,*, Norlaila Mustafa2, Nor Azmi Kamaruddin2 and Munn Sann Lye3
|
| 505 |
8 |
|
|a INTRODUCTIONEpidemiology; Pathophysiology of T2DM; Glycaemic Control; NEW TREATMENT OPTION; Role of SGLTs in Glucose Homoeostasis; Drug Development Status of SGLT Inhibitors; Efficacy of SGLT2 Inhibitors; Safety of SGLT2 Inhibitors; Post-regulatory Approval and Long-term Safety Concerns; EVIDENCE-BASED MEDICINE; Evidence-based Medicine at the Crossroads; Dilemmas in Evidence-based Medicine; Restricted View of Evidence; Limitations of Clinical Trials; Misleading Results; Issues in Translating RCTs to the Clinical Care Arena; The Efficacy-Efficiency Gap; Secondary Research of Evidence Synthesis
|
| 500 |
|
|
|a IL-18
|
| 650 |
|
0 |
|a Diabetes.
|
| 650 |
|
0 |
|a Diabetes
|x Treatment.
|
| 650 |
|
0 |
|a Obesity.
|
| 650 |
|
7 |
|a Diabetes
|2 fast
|
| 650 |
|
7 |
|a Diabetes
|x Treatment
|2 fast
|
| 650 |
|
7 |
|a Obesity
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rehman.
|t Frontiers in Clinical Drug Research - Diabetes and Obesity.
|d Sharjah : Bentham Science Publishers, 2019
|z 9781681084459
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - Diabetes and Obesity Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=5695602
|y Click for online access
|
| 880 |
8 |
|
|6 505-00/(S
|a The Harm of Poor-quality EvidenceCURRENT EFFORTS IN BRIDGING THE EFFICACY-EFFICIENCY GAP; FUTURE RESEARCH; CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; The Effects of Traditional Chinese Medicine on Inflammatory Cytokines in Diabetic Nephropathy: The Progress in the Past Decades; Xiang Tu1, YuanPing Deng2, Ming Chen3, James B. Jordan1 and Sen Zhong1,*; INTRODUCTION; MAJOR INFLAMMATORY CYTOKINES INVOLVED IN DN; Transforming Growth Factor (TGF)-β1; Tumor Necrosis Factor (TNF)-α; Monocyte Chemoattractant Protein-1 (MCP-1); Interleukin (IL)-1; IL-6
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|